Clinical Trials Arena January 20, 2026
Lisa Moneymaker, chief strategy officer at Medidata, highlights the role AI will play in clinical development in 2026.
In 2026, clinical trial design will be reshaped by artificial intelligence (AI)-powered simulation and richer clinical and real-world data. Improvements in and a focus on the patient experience will emerge as a competitive differentiator, driving higher retention and better quality data. Moreover, regulators across geographies, once broadly aligned, are now diverging, forcing sponsors and contract research organisations (CROs) to navigate fragmented expectations. Taken together, these dynamics mark 2026 as a turning point. This will be the year when the clinical trials industry begins to move from exploration to execution, with the groundwork laid over the past years putting clinical trials in a...
Today's Sponsors
Today's Sponsor